ストックスクリーナーアプリを入手
0.00
100.00%
-93.80
アフターアワーズ：
2.65
2.65
+
前日終値:
$93.80
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$80.00M
収益：
-
当期純損益:
$-75.52M
株価収益率:
0.00
EPS:
-2.88
ネットキャッシュフロー:
$-56.92M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$105.00
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
AVTE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
0.00 | 80.00M | 0 | -75.52M | -56.92M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-05-07 | 開始されました | Wedbush | Outperform |
| 2025-05-05 | 開始されました | Stifel | Buy |
| 2025-05-02 | 開始されました | TD Cowen | Buy |
| 2024-06-18 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-06-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-06-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-03-25 | 再開されました | Jefferies | Buy |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2022-12-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-07-26 | 開始されました | Cowen | Outperform |
| 2021-07-26 | 開始されました | Evercore ISI | Outperform |
| 2021-07-26 | 開始されました | Jefferies | Buy |
| 2021-07-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Aerovate Therapeutics Inc (AVTE) 最新ニュース
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded to Buy at Guggenheim - Defense World
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - MarketScreener
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Millennium Management LLC Cuts Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
FMR LLC's Strategic Acquisition of Aerovate Therapeutics Inc Shares - GuruFocus
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC - Defense World
Bank of America Corp DE Has $612,000 Stock Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Investments LP Cuts Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Advisers LP Grows Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Northern Trust Corp Purchases 6,296 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
BNP Paribas Financial Markets Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate Therapeutics (AVTE) Declares Special Dividend Amid Merg - GuruFocus
Aerovate approves reverse split ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics and Jade Biosciences Merger Approved - citybiz
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate (AVTE) Stockholders Approve Merger with Jade Biosciences | AVTE Stock News - GuruFocus
Aerovate Therapeutics Approves Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Inc (AVTE) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):